Safe Fertility Group PCL (BKK:SAFE) ROCE % : 6.82% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Safe Fertility Group PCL ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Safe Fertility Group PCL's annualized ROCE % for the quarter that ended in Dec. 2024 was 6.82%.

Safe Fertility Group PCL ROCE % Historical Data

The historical data trend for Safe Fertility Group PCL's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Safe Fertility Group PCL ROCE % Chart

Safe Fertility Group PCL Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

ROCE %

8.46

16.39

16.27

11.87

Safe Fertility Group PCL Quarterly Data
	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial						13.14	18.91	12.88	8.80	6.82

Safe Fertility Group PCL ROCE % Calculation

Safe Fertility Group PCL's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	217.291	/	( ( (1893.604 - 125.364)	+	(2006.968 - 112.805) )	/ 2 )
	=	217.291	/	( (1768.24	+	1894.163)	/ 2 )
	=	217.291	/	1831.2015
	=	11.87 %

Safe Fertility Group PCL's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	128.424	/	( ( (1980.551 - 107.715)	+	(2006.968 - 112.805) )	/ 2 )
	=	128.424	/	( ( 1872.836	+	1894.163 )	/ 2 )
	=	128.424	/	1883.4995
	=	6.82 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Safe Fertility Group PCL (BKK:SAFE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Safe Fertility Group PCL ROCE % Related Terms

Thank you for viewing the detailed overview of Safe Fertility Group PCL's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Safe Fertility Group PCL Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Safe Fertility Group PCL (BKK:SAFE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ploenchit Road, No. 496, 498, 500, 502 , Amarin Plaza Building, 17th Floor, Lumpini, Pathumwan, Bangkok, THA, 10330

Website

https://www.safefertilitygroup.com

Safe Fertility Group PCL operations include Obstetrics and Gynecology hospital and Medical laboratory and Cosmetic dermatology. Majority of the revenue is generated from Obstetrics and Gynecology hospital business segment and provides treatment services for infertility using medical assisted reproductive technology.